Order Article Reprints

de Souza LR, Magro DO, Teixeira FV, Parra RS, Miranda EF, Féres O, Saad-Hossne R, Soares Prates Herrerias G, Nisihara RM, Coy CSR, et al. Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study. Pharmaceutics. 2023; 15(2):586. https://doi.org/10.3390/pharmaceutics15020586

de Souza, Letícia Rodrigues, Daniela Oliveira Magro, Fábio Vieira Teixeira, Rogério Serafim Parra, Eron Fábio Miranda, Omar Féres, Rogério Saad-Hossne, Giedre Soares Prates Herrerias, Renato Mitsunori Nisihara, Claudio Saddy Rodrigues Coy, and et al. 2023. "Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study" Pharmaceutics 15, no. 2: 586. https://doi.org/10.3390/pharmaceutics15020586

de Souza, L. R., Magro, D. O., Teixeira, F. V., Parra, R. S., Miranda, E. F., Féres, O., Saad-Hossne, R., Soares Prates Herrerias, G., Nisihara, R. M., Coy, C. S. R., Sassaki, L. Y., & Kotze, P. G. (2023). Adalimumab Serum Concentrations, Clinical and Endoscopic Disease Activity in Crohn’s Disease: A Cross-Sectional Multicentric Latin American Study. Pharmaceutics, 15(2), 586. https://doi.org/10.3390/pharmaceutics15020586